top of page

Search

Summit Therapeutics' Jack West on the company's PD-1xVEGF bi-specific vs Keytruda news

blonca9
Jun 1, 2024
1 min read

V.P. of Clinical Operations Jack West gives his interpretation of the announcement that Summit's partner Akeso made in China that it beat Keytruda on PFS head-to-head in 1L lung. He shares his opinion of how this data could translate outside of China and what Summit's development plans are currently.

Recent Posts

Lexeo Therapeutics' CEO Nolan Townsend highlights recent FA cardiomyopathy data and the path ahead in that indication. Plus, the latest on PKP2 ACM, and more

Lexeo Therapeutics' CEO Nolan Townsend highlights recent FA cardiomyopathy data and the path ahead in that indication. Plus, the latest on PKP2 ACM, and more

Metsera's CEO Whit Bernard on the obesity space, including GLP-1s, amylin analogs, and how the company is also developing both as oral peptides

Metsera's CEO Whit Bernard on the obesity space, including GLP-1s, amylin analogs, and how the company is also developing both as oral peptides

On its 10-year anniversary, Arcus Biosciences is taking its 4th molecule into pivotal studies. Co-Founder & CEO Terry Rosen talks HIF-2⍺, TIGIT, and CD73

On its 10-year anniversary, Arcus Biosciences is taking its 4th molecule into pivotal studies. Co-Founder & CEO Terry Rosen talks HIF-2⍺, TIGIT, and CD73

Follow BiotechTV

Also look for unique social pages for BiotechTV U.

Sponsors

NYSE_logo_large_no reg_378x197 (1).png

Learn more about our sponsors

Sponsor Spotlight

Allucent Clinical Research Organization™ is on a mission to help bring new therapies to light by solving the distinct challenges of small and mid-sized biotech companies. We’re a global provider of comprehensive drug development solutions, including consulting, clinical operations, biometrics, and clinical pharmacology across a variety of therapeutic areas.

Learn more about Allucent

bottom of page